SI-B037-ST-101: A Multicenter, Open-Label, Phase 1/1b, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SI-B037 in Adult Patients With Advanced/Metastatic Solid Tumors That Are Refractory to Standard Therapies | Arctuva